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Abstract We analysed the biochemical properties of insulin receptors of a Type A insulin resistant patient with a single heterozygous point mutation 
substituting Gln for Arg 1174. Insulin binding capacity and affinty to Epstein-Barr virus transformed lymphocytes was normal. Quantitative analysis 
of autophosphorylation and substrate phosphorylation of soluble insulin receptors i olated from patient cells revealed no differences in the basal 
state whereas in the presence of insulin autophosphorylation activity was only 30% of control receptors. The stimulation of substrate phosphorylation 
and down-regulation f receptors on patient cells after chronic exposure to insulin was diminished when compared to controls. We conclude that 
the heterozygous Arg 1174 mutation does not perturb asal kinase activity but specifically interferes with the kinase activation by insulin and that the 
mutation has a dominant negative ffect on the wild type kinase. 
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1. Introduction 2. Experimental 
Insulin resistance plays an important role in the pathogenesis 
of non-insulin-dependent diabetes mellitus (NIDDM).  The in- 
sulin receptor is the first site of interaction of insulin with the 
cell and has, therefore, been a major focus of the study of 
genetic auses of insulin resistance. Indeed, many mutations of 
the insulin receptor gene have been identified over the past few 
years in patients with insulin resistance. Inherited defects of the 
insulin receptor gene may cause diminished receptor expression 
[1-6] or impaired receptor function, i.e. insulin binding [7,8] or 
tyrosine kinase activity [9-11]. 
The insulin receptor is an allosteric enzyme consisting of two 
disulfide linked ctfl receptor halves (c¢2~2). Each c~fl receptor half 
is derived from one gene product and is processed into cx and 
fl-subunits during holoreceptor formation [12]. Insulin binding 
to the ~-subunit induces autophosphorylation f tyrosine resi- 
dues on the cytoplasmic domain of the fl-subunit and this re- 
sults in the activation of the tyrosine specific kinase. The phos- 
phorylation of the sites Tyr 1158, Tyr 1152 and Tyr 1163 is critical for 
the activation of the kinase [13]. In this report we describe a 
heterozygous point mutation (Arg n74 -~ Gln) located close to 
the regulatory Tris-phosphorylation site in a patient with Type 
A insulin resistance. Remarkably, the same heterozygous muta- 
tion Arg1174--+ Gln was recently detected in another patient 
with type A insulin resistance [14]. The appearance of the same 
point mutation in two unrelated patients as well as the proxim- 
ity of the mutation to the major regulatory autophosphoryla- 
tion sites suggests that this site is critical for proper functioning 
of the insulin receptor kinase. We therefore, characterize the 
hiherto unknown functional consequences of this mutation 
with particular emphasis on the evaluation of the insulin recep- 
tor kinase and possible dominant negative ffects of the mutant 
allele on the wild type allele. 
*Corresponding author. Fax: (41) (1) 255 4447. 
2.1. Subjects 
The patient, a 19-year-old girl of spanish origin, was severely virilized 
and exhibited a moderate degree of acanthosis nigricans. Both fasting 
blood glucose (9.6 + 1.4 mmol/l), and serum insulin concentrations 
(3020 + 398 pmol/1) as well as haemoglobin-Arc (13.8%) were markedly 
elevated [15]. The patient's resistance towards intravenously adminis- 
tered insulin and the absence of an insulin receptor antibody had previ- 
ously been demonstrated [16]. Control subjects were 6 healthy labora- 
tory staff members. 
2.2. Materials 
Purified sperm wale insulin was a gift from Shimizu Pharmaceutical 
(Shizuoka, Japan). Cyclosporin A was provided by Sandoz Pharma 
Ltd. (Basel, Switzerland). Monoclonal anti-insulin receptor antibody 
(code RPN.538), t25I-insulin, [7-32p]ATP, [c~-33p]ATP and [F-33p]ATP 
and ~4C-labelled lectrophoresis molecular weight markers (Rainbow, 
code CFA.756) were purchased from Amersham (Amersham, Eng- 
land). Wheat-germ-agglutinin (WGA)-agarose gel was purchased from 
E-Y Labs, Inc. (San Mateo, CA) and bovine serum globulin, bovine 
serum albumin, N-acetyl-glucosamine and poly Glu,Tyr (4: 1) from 
Sigma Chemicals Co. (St. Louis, MO). Protein G agarose was obtained 
from Calbiochem corporation (La Jolla, CA). Primers were synthesised 
by Microsynth (Windisch, Switzerland) and the PCR reagent kit was 
purchased from Perkin Elmer Cetus (Norwalk, CT). Sephaglas band 
prep kit was purchased from Pharmacia LKB (Milwaukee, Wisconsin) 
band the Cyclist DNA sequencing kit from Stratagene (La Jolla, CA). 
2.3. Methods 
2.3.1. Transformed lymphocyte culture. EBV-transformed lym- 
phocyte cell lines were established from peripheral blood lymphocytes 
from the patient and 6 normal subjects as described elsewhere [17]. The 
incubation of freshly isolated lymphocytes with conditioned medium of 
marmoset B9518-cells was performed in the presence of 600 ng/ml Cy- 
closporin A. 
2.3.2. Insulin binding. ~zsI-insulin binding to transformed lympho- 
cytes was performed at RT for 2 h as previously described [17]. Insulin 
binding to lectin purified insulin receptors was measured as described 
before [18]. Specific binding was calculated by subtracting non-specific 
from total binding. Non-specific binding, determined with 1/IM unla- 
belled insulin, was less than 2% of total binding. Data were analysed 
using the LIGAND program [19]. 
2.3.3. Preparation of partially purified insulin receptors. EBV-cells 
were washed with phosphate-buffered saline (PBS) and solubilized at 
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4°C during 2 h in a solution of 50 mmol/l HEPES buffer containing 
5 mmol/1 EDTA, 5 mmol/l EGTA, 2% Triton X-100, I mmol/l phenyl 
methyl sulfonyl fluoride, 50 pg/ml leupeptin and 10/.tg/ml aprotinin. 
The soluble fraction was chromatographed over WGA-agarose column 
to isolate the glycoprotein fraction [20]. 
2.3.4. Autophosphorylation assay. Lectin purified insulin recep- 
tors were adjusted for equal insulin binding (4% specific binding at a 
'25I-insulin concentration f 1 ng/ml) and incubated with or without 100 
nM insulin, with 10 mM MgC12and with 4 mM MnCI2 for 30 min at 
RT. The phosphorylation reaction was initiated by the addition of 30 
/ICi [9,-32p]ATP and unlabelled ATP (50 aM final concentration) and 
stopped after 6 min at room temperature byadding EDTA and Na3VO 4 
(final concentration 50mM and 3 mM, respectively). After immunopre- 
cipitation with monoclonal anti-insulin receptor antibody (20 pg/ml) 
and protein G agarose, the receptors were analysed by reducing 7.5% 
polyacrylamide g l electrophoresis and autoradiography. The 32p con- 
tent of the fl-subunit was assessed by excising the band from the dried 
gel and counting its radioactivity. The background as determined by 
excising another area of each lane was subtracted. 
2.3.5. Exogenous ubstrate phosphorylation. WGA-purified insulin 
receptors, adjusted for equal insulin binding, were incubated with 
0.6/IM insulin, 20 mM MgCI2 and 8 mM MnCI2 for 30 min at RT. 40 
aM ATP containing 10/.tCi [~,-32p]ATP and poly Glu,Tyr (4: 1) (final 
concentration 2.5 mg/l) were added for 10, 20 and 30 min at RT (during 
this time the reaction kinetics was linear). Aliquots were spotted on 
discs of Whatman paper (3MMChr) and immediately washed in 10% 
TCA containing 10 mM sodium phosphate and the radioactivity incor- 
porated in the exogenous substrate was determined by liquid scintilla- 
tion counting. 
2.3.6. Insulin receptor down-regulation. EBV-transformed lym- 
phocytes from the patient and control subjects were cultured for at least 
15 h in the absence or presence of 0.3 pM insulin [21]. The cells were 
chilled on ice and washed twice with acidic binding buffer (120 mM 
NaCI, 25 mM KCI, 1.2 mM MgSO 4, 10 mM glucose, 1 mM EDTA, 50 
mM HEPES, 15 mM Na-acetate, BSA 10 mg/ml, pH 4.5) and two times 
with neutral binding buffer (pH 7.8). Specific 125I-insulin binding was 
then determined for 4 h at 4°C [21] and down-regulation was expressed 
as the percentage of insulin binding to cells not chronically treated with 
insulin. 
2.3. 7. Direct sequencing of amplified genomic DNA. Exon specific 
primers described by Seino et al. [22] were used to amplify exon 1-22 
of the insulin receptor gene from genomic DNA of our patient and 
controls. The PCR products of exon 1 22 were excised from a I% 
LMP-agarose gel and subjected to direct sequencing using the Cyclist 
DNA sequencing kit. The oligonucleotides u ed to amplify the DNA 
fragments were end-labelled with [7-32P]ATP and served as sequencing 
primers for the (+) and (-) strand. Amino acids of the insulin receptor 
are numbered according to Ebina et al. [23]. 
3. Results 
3.1. Binding studies 
Maximal specific insulin binding to transformed lympho- 
cytes from the patient was 70% of mean control value and well 
within the normal range (Fig. 1, Table 1). Scatchard analysis 
of competition binding data revealed no affinity differences of 
Table 1 
Scatchard analysis of insulin binding data from EBV-transformed lym- 
phocytes 
Cell line '25I-insulin bound K a Receptors/cell 
(%/2- 106 cells) (nM) 
Controls 13.8 + 6.4 0.164).42 3,357 + 1,620 
Patient 9.7 + 1.4 0.084).26 1,479 + 644 
Binding data were analysed using the LIGAND program. Curve fitting 
and parameter stimation was carried out applying the two site binding 
model. Values for the dissociation constants (Kd) and cell surface recep- 
tor numbers are only indicated for the high-affinity site. Data are 
means + S.D. from 6 normal control subject cell lines and three inde- 
pendent experiments with the cell line of the patient. 
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Fig. 1. Insulin binding studies with EBV-transformed lymphocytes 
from the patient. Values are plotted as the mean + S.D. of three sepa- 
rate experiments. The shaded area represents he mean + S.D. of insu- 
lin binding in transformed cell lines from 6 normal subjects. 
the high-affinity binding site of control and patient receptors 
(Table 1). We found a high degree of variability of insulin 
receptor sites on cells of control subjects (3,350 + 1,600, 
mean + S.D.). The apparent number of receptors on patients 
lymphocytes was (1,500 + 650). 
3.2. Phosphorylation studies 
Table 2 shows that the maximal autophosphorylation capac- 
ity of the patient's WGA purified insulin receptors in the pres- 
ence of 0.1 pM insulin was only 30% compared to the mean 
autophosphorylation capacity of normal control receptors, 
whereas the basal unstimulated autophosphorylation was simi- 
lar. The resulting stimulation factor at 10 -7 M insulin for the 
patient's receptors was therefore 5 times lower than that of the 
control receptors. A representative autoradiogram is shown 
in Fig. 2. The immunoprecipitation efficiency of the 
phosphorylated insulin receptors had minimal variation within 
an experiment. 
Unstimulated phosphorylation of the synthetic substrate 
poly Glu,Tyr (4: 1) by insulin receptors of the patient was 
nearly identical (101% of the mean control value) to the basal 
exogenous kinase activity of control receptors as shown in 
Table 2. In contrast, the stimulation of substrate phosphoryla- 
tion in the presence of 0.6/IM insulin was 2.03-fold with control 
receptors and only 1.37-fold with patient receptors. 
3.3. Insulin receptor down-regulation 
Since kinase activity was shown to be necesarry for insulin 
receptor internalization [21,24-26] we investigated the down- 
regulation capability of the patients EBV-transformed lympho- 
cytes upon chronic exposure (at least 15 h) to 0.3 ~tM insulin. 
Several incubations with insulin treatments ranging from 15 to 
48 h were performed. Down-regulation of cell surface insulin 
receptors after incubation with insulin for 48 h was 65.6 _+ 7.8% 
(mean + SD. ,  n = 3) for control cells and 33.7 + 10.6% for 
patient cells (data not shown). No differences were noted with 
shorter (15 h) exposures to insulin. Also, there is more TCA- 
precipitable ~25I-insulin in supernatants of patient cells than of 
control cells (data not shown), suggesting that there is dimin- 
ished internalization and subsequent degradation of receptor- 
bound insulin. 
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Fig. 2. Representative autoradiogram of autophosphorylated soluble 
insulin receptors inthe absence and presence ofinsulin from two con- 
trol subjects and the patient. WGA-purified insulin receptors from 
EBV-transformed cells of the patient and control subjects were adjusted 
for equal insulin binding capacity (4% of total binding) and auto- 
phosphorylation was assayed with [T-32P]ATP in the absence (-) and 
presence (+) of 0.1 BM insulin as described in section 2. After im- 
munoprecipitation with monoclonal nti-insulin receptor antibody the 
precipitated protein were analysed by 7.5% SDS-PAGE. 
3.4. Sequencing 
By subsequent direct sequencing of all 22 exons of the pa- 
tients insulin receptor gene we detected four known silent pol- 
ymorphisms, each of them in one of the two alleles: Asp 519 
(GAT/C) and Ala 523 (GCG/A) in exon 8, Phe 642 (TTC/T) in 
exon 9 and Tyr 984 (TAC/T) in exon 17. The sequence pattern 
of exon 20 of the patient revealed two bands at the second 
nucleotide in codon 1,174 representing a heterozygous state for 
the point mutation CAG ~ CGG which results in the substitu- 
tion of glutamine for arginine (Fig. 3). 
4. D iscuss ion  
In this report we characterize some of the functional proper- 
ties of a mutation in the insulin receptor gene of a patient with 
the type A syndrome of insulin resistance. This mutation leads 
to the substitution of Gln for Arg 1174 in the fl-subunit of the 
insulin receptor and is present in a heterozygous state. Arg H74 
is located in the proximity to the major regulatory auto- 
phosphorylation site (Tyr 1~58, Tyr 1162 and Tyr 1163) and is a highly 
conserved residue in the family of insulin receptor genes. In all 
other tyrosine kinases the corresponding site is also occupied 
by a basic amino acid, namely a lysine residue [27]. Several 
other mutations in the regulatory domain of the insulin recep- 
tor tyrosine kinase have been reported to alter tyrosine kinase 
activity: Ala 1134 ---) Thr [28], Ala lm --. Glu [29], Met 1153 ~ Ile 
[30], Arg 1164 -~ Gln [31], Trp 1193 --) Leu [32] and Trp 12°° -~ Ser 
[33,34]. 
Two different experimental systems have mainly been used 
to examine the functional properties of mutated receptors: 
(i) Different cell lines (i.e. CHO, NIH-3T3 and COS 7) trans- 
fected with the mutated insulin receptor [28-30,35-38] and 
( i i )  Epstein-Barr virus transformed patient lymphocytes 
[9,11,31,32,39]. The two systems differ profoundly in that the 
mutated receptor gene in transfected cells is present in a 'ho- 
mozygous' tate so that only mutated receptors are synthesised. 
The homogeneity of the receptors ubsequently facilitates the 
biochemical nalysis of receptor functions. Therefore, in most 
recent studies the transfection system was used. However, the 
Arg 1174 mutation, as well as the majority of all receptor kinase 
mutations are in a heterozygous state and therefore, both, mu- 
tated (mt) and wild type (wt) alleles, are expected to be ex- 
pressed. Furthermore, the mature receptor is formed by the 
assembly of two gene products, which have to interact during 
the allosteric activation of the receptor kinase by insulin [20]. 
If both alleles are equally expressed, three possible receptor 
species, wt/wt, wt/mt hybrid and mt/mt receptors could form 
in a expected ratio of 1:2: 1. Within hybrid receptors, the mt 
gene product could impair the wt gene product or the wt could 
largely compensate for a defective mt gene product. In a 'ho- 
mozygous' transfection system, this issue cannot be addressed 
and we therefore, chose to analyse the functional properties of 
the Arg j~74 mutation using EBV transformed patient cells. The 
expected inhomogeneity of receptors necessitates a careful 
quantitative analysis of receptor functions. 
Five parameters were examined: (i) insulin receptor number, 
(ii) affinity of insulin receptor binding, (iii) insulin receptor 
autophosphorylation, (iv) substrate phosphorylation and 
(v) insulin receptor down-regulation. 
Scatchard analysis of competition binding of insulin to EBV 
transformed cells from the patient revealed no significant dif- 
ferences in receptor affinity and receptor number. The insulin 
receptor number of patient cells was lower than the mean value 
of normal control subjects, but it was still within the normal 
range. The observed high degree of variability of insulin recep- 
tor numbers on EBV-transformed cells of normal subjects has 
already previously been documented [17,40]. The finding of 
Table 2 
Comparison of autophosphorylation and substrate phosphorylation activities 
Autophosphorylation Stimulation factor Substrate phosphorylation Stimulation factor 
(PJreceptor) (pmol P~. min -~ • mg -~ substrate) 
- insulin + insulin - insulin + insulin 
Controls 0.35 + 0.08 2.72 + 0.77 7.8 0.19 + 0.06 0.37 + 0.10 2.03 
Patient 0.53 + 0.16 0.81 + 0.26 a 1.5 0.19 + 0.03 0.26 + 0.05 a 1.37 
Autophosphorylation a d substrate phosphorylation studies of partially purified insulin receptors were performed as described in section 2.3. 
Receptors were normalized for insulin binding activity and incorporation ofphosphate inthe absence and presence ofinsulin was quantified by dry 
r-counting of the excised bands from the polyacrylamide g lrepresenting the 92 kDa fl-subunit of the insulin receptor. Phosphorylation data of the 
synthetic substrate poly Glu,Tyr (4 : 1) were assessed by liquid scintillation counting of the dried filter disks containing aliquots of the reaction. Data 
represent the means _+ S.D. in 8 (3 control subjects) and 4 (patient) experiments forthe autophosphorylation and 3 (2 control subjects) and 3 (patient) 
experiments for the substrate phosphorylation. ~'P < 0.001 vs. control subjects. 
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Fig. 3. Partial nucleotide sequence ofexon 20. Genomic DNA of the 
patient (P) and one control subject (C) was amplified using primers 
which flank exon 20. Sequencing was performed as described insection 
2.3. (a) For the patient, the sequencing ladder shows a mutation in 
codon 1,174 at a heterozygous state. (b) The sequences of the normal 
and mutant alleles from codon 1,172-1,176 are indicated. 
normal binding parameters a well as of normal insulin receptor 
mRNA levels (results not shown) suggests that the 1,174 muta- 
tion neither impairs receptor synthesis nor insulin binding. 
To analyse the kinase activity of insulin receptors from the 
patient equal numbers of partially purified insulin receptors 
were subjected to autophosphorylation andsubstrate phospho- 
rylation in the presence or absence of insulin. In the absence 
of insulin neither autophosphorylation n rsubstrate phospho- 
rylation of patient receptors was impaired. However in the 
presence of insulin a marked reduction of autophosphorylation 
and substrate phosphorylation was noted when compared to 
receptors from control cells. Thus the 1,174 mutation appears 
to interfere predominantly with the insulin mediated kinase 
activation process, but does not seem to perturb the kinase in 
its basal state. As emphasized before the heterozygosity of the 
mutation should lead to the formation of 25% fully functional 
wt/wt receptors which in turn should contribute 25% to the 
autophosphorylation capacity of patient receptors when com- 
pared to receptors from control cells. The finding of only 30% 
autophosphorylation activity in patient receptors when com- 
pared to controls shows that in both mt/mt receptors as well 
as mt/wt hybrid receptors, the insulin stimulated auto- 
phosphorylation capacity must be severely reduced. If the wt 
gene product is not influenced by the mt gene product, the 
expected autophosphorylation capacity of patient receptors 
would be 50% of control receptors. In all experiments the auto- 
phosphorylation capacity of patient receptors was well below 
50% of controls and therefore, the mt kinase negatively affects 
the wt kinase, most likely within the hybrid receptor structure 
(mt/wt). This interpretation is consistent with the observation 
that most of those kinase mutations are inherited as a dominant 
trait [9,10,31,32,38]. Furthermore, the in vitro assembly of ki- 
nase defective receptor halves with wt receptor halves also 
results in a dominant inhibition of the kinase activity [41,42]. 
The functional impairment of the patient receptors with the 
1174 mutation, the lack of additional mutations in the insulin 
receptor coding sequence as well as the appearance of the same 
heterozygous mutation in an unrelated patient with a similar 
degree of insulin resistance as our patient suggest hat this 
mutation is likely to be involved in the appearance of insulin 
resistance. However, the heterozygous state of the 1,174 muta- 
tion and of all other heterozygous kinase mutations described 
previously, should result in the synthesis of 25% kinase active 
(wt/wt) receptors. How such a quantitative change of receptor 
should lead to such a severe insulin resistance is subject of 
speculations. We envisage mainly two possibilities: (i) patients 
with a heterozygous insulin receptor mutation may carry an 
additional mutation in a gene encoding a protein involved in 
the intracellular signalling pathway of the receptor or (ii) the 
extremely high plasma insulin levels of the patient (3,020 pmol/ 
1) may aggravate insulin resistance by down-regulating any 
residual functional receptors. The kinase defective receptors 
may preferentially accumulate at the cell surface, since kinase 
activity appears to be required for receptor internalization. 
Though there have been conflicting data on this issue [43], the 
majority of the reports point to a critical role of the kinase for 
receptor mediated endocytosis and down-regulation [21,24- 
26,44]. In accordance, we find a reduced insulin receptor in- 
duced down-regulation in EBV-cells with the kinase mutated 
receptor when compared to EBV-cells with normal receptors. 
Another hint that insulin levels may influence the degree of 
insulin resistance in this patient comes from the observation 
that treatment of our patient with rhlGF I resulted in a pro- 
nounced ecrease of insulin synthesis and an improvement of
hyperglycaemia [15]. A decreased plasma insulin concentration 
might lead to a reduced own-regulation a d the appearance 
of functional insulin receptors at the surface of insulin target 
cells and therefore, result in a increased insulin sensitivity. In 
any case, both, physiological mechanisms a  well as potential 
presence of additional mutations, may contribute to the so far 
unexplained clinical heterogeneity of carriers of insulin receptor 
mutations. 
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